


Stem Cell Investor & Executive Networking Conference Event (SCIENCE)

Hosted by:

NATIONAL
SECURITIES

MD 
BECKER
PARTNERS LLC



June 1, 2010

Program: 11:00am to 4:00pm

Reception: 4:00pm to 5:00pm

120 Broadway, 2nd Floor

New York, NY USA

Register now at:

www.mdbpartners.com/science

The SCIENCE program is strategically designed to unite investors with industry executives to exchange information and highlight opportunities in the expanding stem cell universe.

The event will bring together the founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to offer compelling presentations, share information, and discuss the future of the exciting field.

The agenda includes keynotes and panel discussions, lunch presentations with experts, a focused science/industry track as well as intimate networking opportunities to meet the needs of all attendees. There is no cost to attend and lunch will be provided.

For additional information, including panelist slots and sponsorship opportunities, please contact Michael Becker at **(267) 756-7094** or email at **michael@mdbpartners.com**

Pre-registration for the event is required and attendance limited to 150 individuals, so please register online today at:

www.mdbpartners.com/science

Tuesday, June 1, 2010 – Preliminary Conference Agenda*

10:30am	Registration opens	
10:45am	Mark Goldwasser, President & CEO, National Securities – <i>Opening remarks</i>	
10:50am	Jason Kolbert, Managing Director – Health Care Research, National Securities – <i>A New Model on Wall Street – National’s Effort in the Life Science Space</i>	
11:00am – 11:15am	Rasheda Ali, author and daughter of legendary boxer Muhammad Ali <i>“I’ll Hold Your Hand So You Won’t Fall – A Child’s Guide to Parkinson’s Disease”</i>	
11:15am – 11:30am	Lindsay Rosenwald, M.D., Founder & Chairman, Paramount Group of Companies, <i>“Outlook for Biotechnology Across the Next Decade”</i>	
11:30am – 12:15pm	Panel Discussion <i>“Adult versus Embryonic”</i>	<i>Moderator:</i> Martin Grumet Ph.D.; Professor of Cell Biology and Neuroscience, Division of Life Sciences, Rutgers University <ul style="list-style-type: none"> • Alan Harris, M.D., Ph.D., VP of Regen. Medicine, NeoStem, Inc. • Michael West, Ph.D., CEO, BioTime, Inc. • Michael Schuster, VP Operations, Angioblast Systems, Inc.
12:15pm – 1:15pm	Luncheon <i>“Large company perspectives”</i>	Keynote Speakers (30-minutes each): <ul style="list-style-type: none"> • Robert Hariri, M.D., Ph.D., CEO, Celgene Cellular Therapeutics • Devyn Smith, Senior Director, Strategic Management Group, Pfizer, Inc.
1:15pm – 2:00pm	Plenary Session <i>“Allogeneic Approaches”</i>	<i>Moderator:</i> Anna Kazanchyan, M.D., Managing Director, Primary i-Research, LLC. <ul style="list-style-type: none"> • Rodney Young, CFO, Stem Cells Inc. • Gil Van Bokkelen, Ph.D., Chairman & CEO, Athersys, Inc. • Zami Aberman, CEO, Pluristem Therapeutics, Inc. • Richard Garr, JD, CEO, NeuralStem, Inc.
2:00pm – 2:45pm	Plenary Session <i>“Autologous Approaches”</i>	<i>Moderator:</i> Shaini Cornelio, Ph.D., CSO TSG Pharmaceuticals <ul style="list-style-type: none"> • Rhonnda L. Bartel, Ph.D., CSO, Aastrom Biosciences, Inc. • Robin Smith, M.D., M.B.A., NeoStem, Inc. • Eldad Melamed, M.D., CMO Brainstorm Cell Therapeutics
2:45pm – 3:00pm	Rev. Tomasz Trafny, Head of Science and Faith Department , The Vatican	
3:00pm – 3:45pm	Panel Discussion <i>“View from Investors”</i>	<i>Moderator:</i> Brian Friedman <ul style="list-style-type: none"> • Michael B. Sheffery, Ph.D., Analyst, OrbiMed Advisors • Nicolas Chronos, M.D., Adjunct Partner, Essex Woodlands • Peter Kolchinsky, Ph.D., RA Capital Management • Michael S. Weiss, J.D., Partner, Opus Point Partners
3:45pm	Closing remarks: Michael Becker, President & CEO, MD Becker Partners	
3:50pm – 5:00pm	Networking Reception	

* Subject to change

Special Guests

Rasheda Ali

Author

Rasheda Ali was inspired to write the book, *I'll Hold Your Hand So You Won't Fall – A Child's Guide to Parkinson's Disease*, by watching the interaction between her children and her father, the legendary boxer Muhammad Ali, former three-times World Heavyweight Champion who suffers from Parkinson's disease. Rasheda saw a clear need to help children understand why their loved ones behave a certain way because they have PD. With the book, she wanted to encourage dialogue and set an example of how communication within the family can overcome barriers and unfold its potential to improve the quality of life for the whole family. Rasheda is a tireless caregiver advocate on behalf of families who are fighting Parkinson's disease. She served as Honorary Chairperson on behalf of the Florida Coalition to Cure Parkinson's Disease in 2002 and 2003 and is involved with leading Parkinson's disease organizations in raising awareness for this debilitating disease.



Lindsay A. Rosenwald, M.D.

Founder and Chairman

Paramount Group of Companies

Dr. Rosenwald has founded over 50 companies during his 20+ year career in biotechnology, including most recently founding and selling Cougar Biotechnology to Johnson & Johnson for just under \$1 billion. He managed the Aries Funds from 1994 through 2007, with peak assets under management in 2000 of over \$1 billion dedicated to healthcare investments. From 2002 through 2006 he managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs. Dr. Rosenwald earned his M.D. from Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University. Dr. Rosenwald has launched many successful careers on Wall Street for MDs, PhDs, MBAs, attorneys and related professionals. He continues to support the medical community through his philanthropic foundation.



Special Guests

Mark Goldwasser

President and Chief Executive Officer
National Securities

Mr. Goldwasser comes from a rich background having worked in managerial and executive positions at several of Wall Street's largest firms. Mr. Goldwasser was the Managing Director and Co-head of Global High Yield Sales at ING Barings, the Managing Director of High Yield Sales at Schroders & Co., Vice President of Institutional High Yield Sales at Lazard Freres & Co., and the Associate Director of Institutional Convertible Sales and Institutional High Yield Sales at Bear Stearns & Co., Inc. "Goldie", as he is known in the industry, joined National Securities in mid-2000 and has shown impeccable leadership by bringing the company through the difficult period of September 11 and its aftermath. With extensive experience in international financial markets, "Goldie" has the balance and vision necessary to lead National Securities. Additionally, National Securities has an in-depth team of key management that consist of well experienced executives and expert department heads to complement its vision.



Keynote Speakers:

Robert J. Hariri, M.D., Ph.D.

Chief Executive Officer
Celgene Cellular Therapeutics



Dr. Hariri has combined his unique skills with the inventiveness of a proven serial entrepreneur in two distinct technology sectors; biomedical technology and aerospace. The Founder and Chief Executive Officer of Celgene Cellular Therapeutics, one of the world's largest human cellular therapeutics companies, Dr. Hariri has pioneered the use of human stem cells to treat a range of life threatening diseases. His prior professional experience includes academic neurosurgeon at Cornell University Medical Center, biotechnology executive, military surgeon and aviator. Dr. Hariri has over 50 issued and pending patents, has authored over 100 published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the post-partum placenta and as a member of the team which discovered the physiologic activities of TNF (tumor necrosis factor). Dr. Hariri was awarded the Thomas Alva Edison Award in 2007 for his discovery of placental stem cells.

A jet-rated, multi-engine and instrument commercial pilot with over 5000 hours of flight time in over 60 different military and civilian aircraft, Dr. Hariri is a founder and board member of the Rocket Racing League, an extreme aerospace corporation. Dr. Hariri serves on numerous Boards of Directors including ImmuneRegen (NASDAQ:IRBS), Semorex and Wafergen (NASDAQ:WGBS). Dr. Hariri is a member of the Board of Visitors of the Columbia University Fu Foundation School of Engineering and Applied Sciences and the Science and Technology Council of the Columbia University College of Physicians and Surgeons. Dr. Hariri is a member of the scientific advisory board for the Archon X PRIZE for Genomics, which is awarded by the X Prize Foundation and is a member of the Ivy League Football Association. Dr. Hariri is also a Board Member of the Somerset Patriots, a minor league baseball team.

Dr. Hariri has also produced several feature films and documentaries including the Sundance Film Festival selection *Off the Black* starring Nick Nolte and Academy Award winner Timothy Hutton and *The Diary of Immaculee* and *Crude Independence*.

Dr. Hariri received his undergraduate training at Columbia College and Columbia University School of Engineering and Applied Sciences and was awarded his M.D. and Ph.D. degrees from Cornell University Medical College. Dr. Hariri received his surgical training at The New York Hospital-Cornell Medical Center and directed the Aitken Neurosurgery Laboratory and the Center for Trauma Research.

Keynote Speakers:

Devyn Smith

*Senior Director,
Strategic Management Group*
Pfizer, Inc



Devyn joined Pfizer's Strategic Management Group in August 2009 and is in the lead role supporting Research. In this role, Devyn's primary responsibility is to partner with Rod MacKenzie and members of the Research Leadership Team to develop and implement business strategies and operational plans. In addition, Devyn is a member of Ruth McKernan's leadership team in the Regenerative Medicine Research Unit. The focus of much of his work in Regenerative Medicine has been around creating successful business models and commercialization strategy for Regenerative Medicine products. This has resulted in several publications and multiple invited speaking engagements.

Prior to joining Pfizer, Devyn was a principal for The Frankel Group (a boutique management consulting firm in New York City and Cambridge). In his consulting experience, Devyn led a wide range of projects, across multiple therapeutic areas and a host of technology platforms, including a strong focus in regenerative medicine managing over 30 engagements in this space. Prior to joining The Frankel Group, Devyn worked as a management consultant at Adventis Corporation focused on clients in information intensive companies.

Devyn received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an MS in Biology from Idaho State University and a BS in Zoology from Brigham Young University.

Conference Co-chairs:

Jason Kolbert

Managing Director and the Head of Healthcare Research
National Securities Corporation



Jason's career began as a chemist in the pharmaceutical industry and evolved into a product and marketing manager with Schering-Plough in Japan. Upon returning from Japan Jason joined Salmon Smith Barney as a research associate, became an analyst and rose to be the health care strategist for the firm, integrating the views of pharma, biotech, specialty pharma and services analyst into a comprehensive strategy for portfolio managers. His quarterly reports have been featured in Barrons and he has made numerous appearances on television throughout his Wall Street career. Jason left Citigroup in 2002 and joined the buy side with Susquehanna International Group where he managed a long short fund for four years. He then founded the biotechnology sell side effort at Susquehanna and built a team of five persons covering several therapeutic categories. Jason is known today for his coverage of the Hepatitis, Stem Cell Therapy and Bio-Defense sub-sectors.

Jason has an undergraduate degree in Chemistry from SUNY New Paltz where he graduated with honors and a graduate degree in finance from University of New Haven. Jason also has an honorable discharge from the Marine Corps PLC flight program. He is an avid marathon runner, although these days it's more half marathons. He is married to Mayumi with two boys where he keeps a Japanese style home where the spoken language is Japanese.

NATIONAL
SECURITIES

Conference Co-chairs:

Michael Becker

Founder, President and Chief Executive Officer

MD Becker Partners LLC



Mr. Becker has more than 15-years of experience as a serial entrepreneur, C-level industry executive, drug developer, Wall Street securities analyst and registered financial advisor.

Before establishing MD Becker Partners LLC in 2008, he served as president, chief executive officer, and member of the Board of Directors for several publicly-traded biotechnology companies including commercial-stage Cytogen Corporation (acquired by EUSA Pharma) and development-stage VioQuest Pharmaceuticals, Inc.

During his tenure at Cytogen, Mr. Becker raised in excess of \$130 million in new capital through both public offerings and private placements and in-licensed Caphosol®, a topical oral agent and prescription medical device for the treatment of oral mucositis and xerostomia.

Prior to joining Cytogen, Mr. Becker was with Wayne Hummer Investments LLC, a Chicago-based regional brokerage firm, where he held senior positions as a biotechnology securities analyst, financial advisor and portfolio manager. He was also the founder and Executive Editor of Beck on Biotech, a monthly biotechnology investment newsletter published from July 1998 through March 2001. Mr. Becker was previously with Kidder, Peabody & Co., Gruntal & Co., L.L.C., and Kemper Securities.

Mr. Becker plays an active leadership role as an advocate for the biotechnology industry. He is past Chairman and member of the board of trustees with BioNJ, which is New Jersey's trade association for biotechnology companies, and is currently a member of BioNJ, Pennsylvania Bio, the New Jersey Technology Council (NJTC), and the Pharmaceutical Consulting Consortium, Inc. (PCCI). Mr. Becker placed as a biotechnology/life sciences finalist for the Ernst & Young Entrepreneur of the Year award in both 2004 and 2005 and was listed in BusinessWeek's "CEO's 40 and Under" article in December 2006. He attended DePaul University in Chicago, Illinois.

MD 
BECKER
PARTNERS LLC

About the Hosts:

National Securities Corporation



National Securities Corporation, a wholly-owned subsidiary of National Holdings Corporation (OTCBB: NHLD.OB), is an international full service independent brokerage firm with a diverse base of retail and institutional clients. National Holdings Corporation is a holding company for National Securities Corporation, vFinance Investments, Inc., EquityStation, Inc., National Asset Management, Inc., and National Insurance Corporation. National Securities, vFinance and EquityStation are broker-dealers registered with the SEC, and members of FINRA and SIPC. vFinance is also a member of the NFA. The three principal lines of business of the broker-dealers are offering full service retail brokerage; providing investment banking, merger, acquisition and advisory services to micro, small and mid-cap high growth companies; and trading securities, including making markets in over 4,000 micro and small-cap stock, distributing direct market access platforms, and providing liquidity in the United States Treasury marketplace. National Asset Management is a federally-registered investment advisor. National Insurance provides a full array of fixed insurance products to its clients. For more information please visit www.nationalsecurities.com and www.vfinance.com.

MD Becker Partners LLC



MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry, including pharmaceuticals, biotechnology, and medical devices. The firm also works with venture capitalists, institutional investors, and others that provide capital to these companies. As a strategic supporter and partner, everything MD Becker Partners does is focused on helping its clients increase visibility, unlock stakeholder value and access resources to grow their business. To accomplish this, the firm integrates strategy, relations, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. In addition, MD Becker Partners limits its client base in order to provide the personalized and dedicated service that only a boutique firm can offer. For more information, visit the company's website at: www.mdbpartners.com and online newsletter at www.lifesciencedigest.com.

Detailed Biographies:

Rasheda Ali

Rasheda Ali was inspired to write the book, *I'll Hold Your Hand So You Won't Fall – A Child's Guide to Parkinson's Disease*, by watching the interaction between her children and her father, the legendary boxer Muhammad Ali, former three-times World Heavyweight Champion who suffers from Parkinson's disease. Rasheda saw a clear need to help children understand why their loved ones behave a certain way because they have PD. With the book, she wanted to encourage dialogue and set an example of how communication within the family can overcome barriers and unfold its potential to improve the quality of life for the whole family. Rasheda is a tireless caregiver advocate on behalf of families who are fighting Parkinson's disease. She served as Honorary Chairperson on behalf of the Florida Coalition to Cure Parkinson's Disease in 2002 and 2003 and is involved with leading Parkinson's disease organizations in raising awareness for this debilitating disease.

Lindsay A. Rosenwald, M.D., Founder and Chairman, Paramount Group of Companies

Dr. Lindsay A. Rosenwald is the Founder and Chairman of the Paramount Group of Companies. These include the following: Paramount BioSciences, which is a global pharmaceutical development and healthcare investment firm that conceives, nurtures, and supports new biotechnology companies; Paramount Corporate Development, which facilitates drug development and corporate development activities for Paramount's portfolio companies; and Paramount BioCapital, which is a FINRA-registered broker-dealer that raises capital for Paramount's portfolio companies and has raised approximately \$950,000,000 since inception.

Dr. Rosenwald has been a Wall Street biotechnology entrepreneur for over 18 years. The senior level professionals at the Paramount Group of Companies are PhDs, MDs, MBAs, attorneys, accountants and related professionals who have significant experience in the life-sciences and financial industries.

Since receiving his medical degree from Temple University School of Medicine in 1983, Dr. Rosenwald has been instrumental in the founding and re-capitalization of dozens of public and private biotechnology and life-sciences companies. Dr. Rosenwald believes these companies are revolutionizing the growth and development of new medicines for the 21st century. Paramount's portfolio companies currently have dozens of compounds in clinical trials.

Dr. Rosenwald believes that the biotechnology industry will experience rapid growth over the next 20 years as the demand for safer and more effective treatments are met with medical breakthroughs, leading to the effective treatment of diseases such as cancer and heart disease. Dr. Rosenwald believes that these revolutionary technologies will be developed not by large pharmaceutical companies, but rather by the smaller biotechnology and life-sciences companies that are each dedicated to the development of a few select products.

Dr. Rosenwald has launched many successful careers on Wall Street for MDs, PhDs, MBAs, attorneys and related professionals. He continues to support the medical community through his philanthropic foundation.

Robert J. Hariri, M.D., Ph.D., Chief Executive Officer, Celgene Cellular Therapeutics

Dr. Hariri has combined his unique skills with the inventiveness of a proven serial entrepreneur in two distinct technology sectors; biomedical technology and aerospace. The Founder and Chief Executive Officer of Celgene Cellular Therapeutics, one of the world's largest human cellular therapeutics companies, Dr. Hariri has pioneered the use of human stem cells to treat a range of life threatening diseases. His prior professional experience includes academic neurosurgeon at Cornell University Medical Center, biotechnology executive, military surgeon and aviator. Dr. Hariri has over 50 issued and pending patents, has authored over 100 published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the post-partum placenta and as a member of the team which discovered the physiologic activities of TNF (tumor necrosis factor). Dr. Hariri was awarded the Thomas Alva Edison Award in 2007 for his discovery of placental stem cells.

A jet-rated, multi-engine and instrument commercial pilot with over 5000 hours of flight time in over 60 different military and civilian aircraft, Dr. Hariri is a founder and board member of the Rocket Racing League, an extreme aerospace corporation. Dr. Hariri serves on numerous Boards of Directors including ImmuneRegen (NASDAQ:IRBS), Semorex and Wafergen (NASDAQ:WGBS). Dr. Hariri is a member of the Board of Visitors of the Columbia University Fu Foundation School of Engineering and Applied Sciences and the Science and Technology Council of the Columbia University College of Physicians and Surgeons. Dr. Hariri is a member of the scientific advisory board for the Archon X PRIZE for Genomics, which is awarded by the X Prize Foundation and is a member of the Ivy League Football Association. Dr. Hariri is also a Board Member of the Somerset Patriots, a minor league baseball team.

Dr. Hariri has also produced several feature films and documentaries including the Sundance Film Festival selection *Off the Black* starring Nick Nolte and Academy Award winner Timothy Hutton and *The Diary of Immaculee* and *Crude Independence*.

Dr. Hariri received his undergraduate training at Columbia College and Columbia University School of Engineering and Applied Sciences and was awarded his M.D. and Ph.D. degrees from Cornell University Medical College. Dr. Hariri received his surgical training at The New York Hospital-Cornell Medical Center and directed the Aitken Neurosurgery Laboratory and the Center for Trauma Research.

Devyn Smith, Senior Director, Strategic Management Group, Pfizer, Inc

Devyn joined Pfizer's Strategic Management Group in August 2009 and is in the lead role supporting Research. In this role, Devyn's primary responsibility is to partner with Rod MacKenzie and members of the Research Leadership Team to develop and implement business strategies and operational plans. In addition, Devyn is a member of Ruth McKernan's leadership team in the Regenerative Medicine Research Unit. The focus of much of his work in Regenerative Medicine has been around creating

successful business models and commercialization strategy for Regenerative Medicine products. This has resulted in several publications and multiple invited speaking engagements.

Prior to joining Pfizer, Devyn was a principal for The Frankel Group (a boutique management consulting firm in New York City and Cambridge). In his consulting experience, Devyn led a wide range of projects, across multiple therapeutic areas and a host of technology platforms, including a strong focus in regenerative medicine managing over 30 engagements in this space. Prior to joining The Frankel Group, Devyn worked as a management consultant at Adventis Corporation focused on clients in information intensive companies.

Devyn received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an MS in Biology from Idaho State University and a BS in Zoology from Brigham Young University.

Jason Kolbert, Managing Director and the Head of Healthcare Research, National Securities Corporation

Jason Kolbert is the Head of Research and senior biotechnology analyst at National Securities.

Jason's career began as a chemist in the pharmaceutical industry and evolved into a product and marketing manager with Schering-Plough in Japan. Upon returning from Japan Jason joined Salmon Smith Barney as a research associate, became an analyst and rose to be the health care strategist for the firm, integrating the views of pharma, biotech, specialty pharma and services analyst into a comprehensive strategy for portfolio managers. His quarterly reports have been featured in Barrons and he has made numerous appearances on television throughout his Wall Street career. Jason left Citigroup in 2002 and joined the buy side with Susquehanna International Group where he managed a long short fund for four years. He then founded the biotechnology sell side effort at Susquehanna and built a team of five persons covering several therapeutic categories. Jason is known today for his coverage of the Hepatitis, Stem Cell Therapy and Bio-Defense sub-sectors.

Jason has an undergraduate degree in Chemistry from SUNY New Paltz where he graduated with honors and a graduate degree in finance from University of New Haven. Jason also has an honorable discharge from the Marine Corps PLC flight program. He is an avid marathon runner, although these days its more half marathons. He is married to Mayumi with two boys where he keeps a Japanese style home where the spoken language is Japanese.

Michael D. Becker, Founder, President and Chief Executive Officer, MD Becker Partners LLC

Mr. Becker has more than 15-years of experience as a serial entrepreneur, C-level industry executive, drug developer, Wall Street securities analyst and registered financial advisor.

Before establishing MD Becker Partners LLC in 2008, he served as president, chief executive officer, and member of the Board of Directors for several publicly-traded biotechnology companies including commercial-stage Cytogen Corporation (acquired by EUSA Pharma) and development-stage VioQuest Pharmaceuticals, Inc.

While at Cytogen, Mr. Becker held positions of increasing responsibility, including Vice President of Business Development, Industry Relations, Investor Relations and Chief Executive Officer of AxCell Biosciences, a subsidiary of Cytogen focused on signal transduction pathways. During his tenure at Cytogen, Mr. Becker raised in excess of \$130 million in new capital through both public offerings and private placements and in-licensed Caphosol(c), a topical oral agent and prescription medical device for the treatment of oral mucositis and xerostomia.

Prior to joining Cytogen, Mr. Becker was with Wayne Hummer Investments LLC, a Chicago-based regional brokerage firm, where he held senior positions as a biotechnology securities analyst, financial advisor and portfolio manager. He was also the founder and Executive Editor of Beck on Biotech, a monthly biotechnology investment newsletter published from July 1998 through March 2001. Mr. Becker was previously with Kidder, Peabody & Co., Gruntal & Co., L.L.C., and Kemper Securities. He has previously held the following financial licenses: Series 7 (Registered Representative), Series 16 (Securities Analyst), Series 63 (Uniform Securities Agent) and Series 65 (Registered Investment Advisor).

Mr. Becker plays an active leadership role as an advocate for the biotechnology industry. He is past Chairman and member of the board of trustees with BioNJ, which is New Jersey's trade association for biotechnology companies, and is currently a member of BioNJ, Pennsylvania Bio, the New Jersey Technology Council (NJTC), and the Pharmaceutical Consulting Consortium, Inc. (PCCI). Mr. Becker placed as a biotechnology/life sciences finalist for the Ernst & Young Entrepreneur of the Year award in both 2004 and 2005 and was listed in BusinessWeek's "CEO's 40 and Under" article in December 2006. He attended DePaul University in Chicago, Illinois.

Rev. Tomasz Trafny, Head of Science and Faith Department, Executive Director of STOQ Project, Pontifical Council for Culture

<biography needed>

Dr. Martin Grumet, Professor of Cell Biology and Neuroscience, Division of Life Sciences, Rutgers University

Dr. Martin Grumet is Professor of Cell Biology and Neuroscience in the Division of Life Sciences at Rutgers University. He joined the W.M. Keck Center for Collaborative Neuroscience as Associate Director in 1999 to work on spinal cord injury and served as Director from 2002-2009. His expanding interest and work in stem cells led him to found in 2006 the Rutgers Stem Cell Research Center and he has served as its Director since its inception. His lab currently focuses on applications of rodent and human stem cells to neurological disorders in spinal cord injury. Dr. Grumet also works on molecular approaches to improve recovery after spinal cord injury focusing on alleviating secondary damage sub-acutely. He has collaborated with corporate partners to investigate siRNA therapy and stem cells in rat models for spinal cord injury. He served on the Scientific Advisory Network of Acorda Therapeutics Inc. for more than a decade. While at NYUMC he worked on primary human brain tumors and serves on the Professional Advisory Board of the Children's Brain Tumor Foundation. He has published over 100 research articles and served on many governmental and academic committees to review grants, papers, organizations and facilities for over 20 years.

Dr. Grumet received his B.Sc. in Physics from The Cooper Union, his Ph.D. in Biophysics at Johns Hopkins University, and did a Post-Doctoral Fellowship in Developmental and Molecular Biology at The Rockefeller University with the Nobel Laureate Dr. Gerald M. Edelman.

Brian Friedman, Senior Managing Director, Head of Healthcare Investment Banking, National Securities

Brian Friedman is a Senior Managing Director and Head of Healthcare Investment Banking at National Securities. Mr. Friedman has worked on Wall Street for over thirteen years as an agent, principal and operator. Mr. Friedman joined National Securities in 1997 as an Associate in the investment banking department and in early 2002, Mr. Friedman assisted in a management buyout and turn-around of National Securities. Since that time, Mr. Friedman worked directly with the new Chairman/CEO to grow the Company from 250 professionals to 750 professionals with revenues increasing from \$40 million to \$130 million. From 2004 to 2010, Mr. Friedman served as an Executive Vice President and Head of Investment Banking at National.

Mr. Friedman has completed over 40 Capital Markets and M&A transactions in a diverse group of industries, including: Healthcare, Energy & CleanTech, Technology and Financial Services.

In 2001, Mr. Friedman founded Robotic Ventures, a venture capital fund specializing in robotics and artificial intelligence companies. The fund made successful investments in early stage and start-up companies such as iRobot (NASDAQ: IRBT) and Mako Surgical (NASDAQ: MAKO). Mr. Friedman began his career as an associate at Liberty Hampshire where he helped structure, raise capital, and operate a special purpose finance company that grew to over \$1.0 billion under management. Mr. Friedman earned his B.A. from the University of Iowa and J.D. and M.B.A. from IIT.

Peter Kolchinsky, Managing Director, Portfolio Manager, RA Capital

Peter Kolchinsky is the Managing Director and Portfolio Manager of RA Capital, a Boston-based healthcare and life-sciences fund focused on companies that develop drugs, diagnostics, and medical device products. He is a member of the National Academies Board on Global Science and Technology, serves as an advisor to companies and non-profits, and is the author of "The Entrepreneur's Guide to a Biotech Startup". He has a Ph.D. in Virology from Harvard University and a BS in Biology from Cornell University.

Mark Goldwasser, President and Chief Executive Officer, National Securities

Mr. Goldwasser comes from a rich background having worked in managerial and executive positions at several of Wall Street's largest firms. Mr. Goldwasser was the Managing Director and Co-head of Global High Yield Sales at ING Barings, the Managing Director of High Yield Sales at Schroders & Co., Vice President of Institutional High Yield Sales at Lazard Freres & Co., and the Associate Director of Institutional Convertible Sales and Institutional High Yield Sales at Bear Stearns & Co., Inc. "Goldie", as he is known in the industry, joined National Securities in mid-2000 and has shown impeccable leadership by bringing the company through the difficult period of September 11 and its aftermath. With extensive

experience in international financial markets, "Goldie" has the balance and vision necessary to lead National Securities. Additionally, National Securities has an in-depth team of key management that consist of well experienced executives and expert department heads to complement its vision.

Anna Kazanchyan, M.D., Managing Director, Primary i-Research

Dr. Kazanchyan is a Managing Director at Primary i-Research, a provider of highly customized scientific, medical and financial due diligence to leading healthcare hedge funds and mutual funds through access to its 4,000+ member global network of clinical and non-clinical experts. Earlier in her career, during 1999-2003, she was a member of the #1 and #2 Institutional Investor (II)-ranked Biotech Equity Research Teams at Goldman Sachs and Salomon Smith Barney, respectively, and afterwards a senior biotechnology research analyst at Wachovia Securities and Investec. From 2003-05, she provided strategic advice and business development services to biopharmaceutical companies' CEOs in addition to overseeing investor relations. She was born and raised in Yerevan, Armenia and is fluent in Armenian and Russian. Anna received her B.A. in Biology, summa cum laude, from Clark University in 1992, and her M.D. from Harvard Medical School in 1996.

Zami Aberman, Chairman & CEO, Pluristem

Mr. Zami Aberman Chairman & CEO joined Pluristem in September 2005 and changed the Company's strategy towards cellular therapeutics. Mr. Aberman's vision to use the maternal section of the Placenta (Decidua) as a source for cell therapy combined with Pluristem's 3D culturing technology led to the development of company unique products. Mr. Aberman has 20 years of experience in marketing and management in the high technology industry. He has held positions of Chief Executive Officer and Chairman in Israel, the USA, Europe, Japan and Korea. He has operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, software, chip design and robotics. Mr. Aberman serves as the Chairman of Rose Hitech Ltd., a private investment company; He has served in the past as the Chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP and as a Director of Ori Software Ltd., a company involved in data management. Prior to that, he served as the President and CEO of Elbit Vision Systems (EVSNF.OB), which supplies inspection systems for the microelectronic industry. In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel. Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben-Gurion University in Israel.

Ronnda L. Bartel, Ph.D., Chief Scientific Officer

Dr. Bartel joined Aastrom in 2006 and is responsible for research, development and manufacturing and engineering operations. Dr. Bartel has more than 20 years of research and product development experience and most recently was Executive Director, Biological Research at Microslet and Vice president, Scientific Development at StemCells Inc. Earlier in her career, she was Senior Principal Scientist, Cell Biology at Advanced Tissue Sciences and was involved in the development and approval of two of the first three cell based products approved by the FDA. She has also worked as Senior Director, Science and Technology at SRS Capital, LLC evaluating life science investments and has also held positions in clinical development, drug delivery, business development and manufacturing. Dr. Bartel

holds a Ph.D. in Biochemistry from the University of Kansas, completed postdoctoral work at the University of Michigan and received a B.A. in Chemistry and Biology from Tabor College.

Robin L. Smith, M.D., MBA, Chief Executive Officer, Chairman of the Board, Neostem

Dr. Robin L. Smith joined the Company as Chairman of its Advisory Board in September 2005 and, effective June 2, 2006, became the Chief Executive Officer and Chairman of the Board. Dr. Smith, who received a medical degree from Yale University in 1992 and a master's degree in business administration from the Wharton School in 1997, brings to the Company extensive experience in medical enterprises and business development. From 2000 to 2003, Dr. Smith served as President & Chief Executive Officer of IP2M, a multi-platform media company specializing in healthcare. During her term, the company was selected as being one of the 10 fastest growing technology companies in Houston. IP2M was sold to a publicly-traded company in February 2003. Previously, from 1998 to 2000, she was Executive Vice President and Chief Medical Officer for HealthHelp, Inc., a National Radiology Management company that managed 14 percent of the healthcare dollars spent by large insurance companies.

Dr. Smith has acted as a senior advisor and investor to both publicly traded and privately held companies where she has played a significant role in restructuring and or growing the companies. Dr. Smith served on the Board of Directors of two privately held companies, Talon Air and Biomega, and also served on the Chemotherapy Foundation Board of Trustees and The New York Theatre Ballet. She currently serves on the Board of Trustees of the NYU Medical Center Board, is past Chairman of the Board of Directors for the New York University Hospital for Joint Diseases where she headed up new development efforts and board member recruitment, and served on the Board of Choose Living. Dr. Smith is the President and serves on the Board of Directors of The Stem for Life Foundation.

Richard Garr, JD, CEO, NeuralStem, Inc.

Richard Garr, JD, has been a director and our Chief Executive Officer since 1996. Mr. Garr was previously an attorney with Beli, Weil & Jacobs, the B&G Companies, and Circle Management Companies. Mr. Garr is a graduate of Drew University (1976) and the Columbus School of Law, The Catholic University of America (1979). Additionally, he was a founder and current Board member of the First Star Foundation, a children's charity focused on abused children's issues; a founder of The Starlight Foundation Mid Atlantic chapter, which focuses on helping seriously ill children; and is a past Honorary Chairman of the Brain Tumor Society.

Michael David West, Ph.D., CEO, BioTime, Inc.

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase

diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines.

Shalini Cornelio, PhD, Chief Operating Officer, Chief Scientific Officer, TSG Pharmaceuticals

Shalini Cornelio, PhD, is the Chief Operating Officer and Chief Scientific Officer of TSG Pharmaceuticals, a privately-held biopharmaceutical company. She previously led global healthcare investments at Alexandra Investment Management, a multi-strategy hedge fund, and was a Partner at Maximus Capital, a healthcare hedge fund. Prior to that, she was a biotechnology equity research analyst at CIBC and at Citigroup, where she was a member of an award-winning team in the annual Institutional Investor poll. Shalini received a PhD from the University of Notre Dame and was a postdoctoral fellow and scientist at Memorial Sloan Kettering Cancer Center.

Alan G. Harris, MD, PhD, Vice President of Regenerative Medicine, Drug Development and Regulatory Affairs, NeoStem Inc.

Dr. Harris has been Vice President of Regenerative Medicine, Drug Development and Regulatory Affairs since July 2009. Prior to joining us, he was Senior Vice President and Chief Medical Officer of NPS Pharmaceuticals Inc, a Biotechnology Company focused on the development of therapeutics for rare gastrointestinal and endocrine disorders with high-unmet medical needs. From February 2006 to December 2007 he was Chief Medical Officer of Manhattan Pharmaceuticals, Inc., a specialty healthcare product company focused on developing products for obesity and psoriasis. Prior to this, from January 2004, Dr. Harris was head of the Worldwide Medical Endocrine Care group at Pfizer, Inc. (NYSE: PFE) in New York City, where he oversaw the Medical Affairs clinical development of the growth hormone Genotropin® for the treatment of pediatric short stature conditions and of GH deficiency in adults, Pegylated GH antagonist Somavert®, for the treatment of GH producing tumors. Prior to Pfizer he served in a number of capacities at Schering-Plough Corporation (Kenilworth, NJ) from 1995 to 2003, most recently as vice president, Global Healthcare Research & Outcomes, where he represented the Medical Affairs Department at Schering Plough in the joint venture with Merck in the clinical development of the novel cholesterol absorption inhibitor medication, ezetimibe (Zetia®). Other responsibilities at Schering-Plough included Medical Affairs research in products (Claritin®, Nasonex®, Asmanex®) for the treatment of allergic conditions and asthma, Hepatitis C (Peg-Intron®) and Cardiovascular and Metabolic diseases. During his tenure at Sandoz (Novartis) Pharmaceuticals in Basel, Switzerland (1984-1991), Dr. Harris headed the clinical development of the first long-acting somatostatin analog, octreotide (Sandostatin®), approved worldwide for the treatment of hormone producing gastrointestinal endocrine tumors (carcinoids, VIPomas) and growth hormone producing tumors (acromegaly). Dr Harris received an M.D.

degree cum laude from the Louis Pasteur Faculty of Medicine, University of Strasbourg, France and a Ph.D. in Endocrinology from Erasmus University, Rotterdam, The Netherlands. He is currently an adjunct professor of medicine at New York University Medical School and visiting professor of medicine in the Department of Endocrinology at Liege University Medical School, Belgium and in the Department of Pharmacology and Clinical Toxicology at the University Hospital of Lausanne, Switzerland. Dr. Harris is a Fellow of the American College of Physicians, the Royal College of Physicians (UK). Dr. Harris was Associate Professor of Medicine of UCLA School of Medicine, Director of the Division of Clinical Pharmacology in the Department of Medicine with a joint appointment as Medical Director of the Department of Technology Development and Transfer and Clinical Trials at Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles (1992-1994). He was co-chairman of the R&D Sub Committee of the Biotechnology Industry Organization (BIO) (1992-1998) and has served on the NIH Center for Scientific Review Special Emphasis Panel for Clinical Cardiovascular Sciences Study Section from 1998 – 2002. Dr. Harris served on the editorial boards of several international peer reviewed medical journals and has authored 120 peer reviewed scientific papers.

Michael B. Sheffery, Ph.D., OrbiMed Advisors

Dr. Sheffery is a founding General Partner of OrbiMed. Dr. Sheffery was formerly Head of the Laboratory of Gene Structure and Expression at Memorial Sloan-Kettering Cancer Center. He received both his Ph.D. in Molecular Biology and his B.A. in Biology from Princeton University. Dr. Sheffery joined Mehta and Isaly in 1996 as a Senior Analyst covering the biotechnology industry.

Nicolas Chronos, MD, Essex Woodlands Health Ventures

Nicolas A. S. Chronos, M.D., is the President and CEO of Saint Joseph's Translational Research Institute (SJTRI) and Adjunct Professor of Medicine at Duke University Medical Center. He currently oversees preclinical trials and clinical research at SJTRI. Dr. Chronos is a renowned researcher in the areas of stem cell therapy and cardiovascular regeneration, and has extensive experience in the development and assessment of interventional cardiology devices. In June 1999, Dr. Chronos co-founded ACRI, a non-profit organization dedicated to promoting and improving the comprehensive care of the cardiovascular patient. ACRI was acquired by St. Joseph's Hospital of Atlanta and became the St. Joseph's Translational Research Institute. Dr. Chronos was named Director of Research at the Andreas Gruentzig Cardiovascular Center at Emory University Hospital in 1997. He is a frequent international lecturer and an author of numerous publications.

Dr. Chronos joined Essex Woodlands in August 2006 and serves on the Board of Directors for Medlogics Device Corporation (<http://www.medlogics.com>). He is a Fellow of the Royal College of Physicians (London), Fellow of the American College of Cardiology, Fellow of the European Society of Cardiology, and Fellow of the American Heart Association. He sits on numerous scientific and medical Advisory Boards and has served as Study Section Chair, SBIR, Cardiovascular Science, for the National Institutes of Health and on the Data Safety Monitoring Boards for numerous clinical trials. In addition, Dr. Chronos has co-founded several successful biotechnology companies. Dr. Chronos received a Bachelors of

Science in Medicine and Surgery from the Royal Free Hospital School of Medicine in London and conducted research in thrombosis at Emory University School of Medicine.

Michael S. Weiss, Opus Point Partners

Michael Weiss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer at Cravath, Swaine & Moore. From 1993 through 1999, he worked with Dr. Rosenwald in managing the Aries Funds. In 1999, Mr. Weiss founded Access Oncology which was later acquired by Keryx Biopharmaceuticals (NASDAQ: KERX) in 2004. Following the merger, Mr. Weiss remained as CEO of Keryx and grew Keryx to close to a \$1BB market capitalization company at its peak. While at Keryx, he raised over \$150MM in equity capital through public and private offerings, executed a \$100MM+ strategic alliance, negotiated multiple SPA agreements with the FDA and managed multiple large clinical trials.